We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Mindy M. Chou
Mindy M. Chou
Products
PRODUCTS
Fresenius Kabi USA, LLC
Jazmine N. Brown
and
Mindy M. Chou
Price:
$117.00
View
Advanced Accelerator Applications USA, Inc.
Mindy M. Chou
,
Robin P. Mathew
, and
Victoria Spivak
Price:
$117.00
View
Steri-Pharma, LLC
Mindy M. Chou
,
Natasha Gupta
, and
Gam S. Zamil
Price:
$117.00
View
Sciegen Pharmaceuticals, Inc.
Sayyem H. Akbar
,
Mindy M. Chou
, and
Karishma G. Gopaul
Price:
$117.00
View
RK Pharma, Inc.
Mindy M. Chou
,
Samir C. Gala
, and
Gam S. Zamil
Price:
$117.00
View
Akorn Operating Co., LLC
Mindy M. Chou
,
Natasha Gupta
,
Ko U. Min
,
Guerlain Ulysse
, and
Nicholas A. Violand
Price:
$117.00
View
Precision Nuclear of Virginia
Mindy M. Chou
and
Brandy N. Lepage
Price:
$117.00
View
WES Pharma, Inc.
Mindy M. Chou
and
Natasha Gupta
Price:
$117.00
View
Compounded Solutions in Pharmacy, LLC
Johnna L. Bleem
and
Mindy M. Chou
Price:
$117.00
View
Berkshire Sterile Manufacturing, Inc.
Mindy M. Chou
and
Daniel L. Zheng
Price:
$117.00
View
View All Products by Mindy M. Chou
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
